Definium Therapeutics Q2 net loss widens on higher warrant costs
DFTX•Clinical update and outlook
Definium announced positive Phase 3 results for its lead candidate in major depressive disorder.
It expects topline data from the Phase 3 Voyage study in generalized anxiety disorder in the week of August 10, 2026, and topline results from the Phase 3 Panorama study in generalized anxiety disorder in September 2026.
Quarterly figures and analyst view
Key details from the quarter included:
| Metric | Actual |
|---|---|
| Q2 loss per share | $1.44 |
| Q2 net loss | $158.99 million |
| Q2 income from operations | -$75.08 million |
| Q2 operating expenses | $75.08 million |
The current average analyst rating on the shares is "buy," with 17 "strong buy" or "buy" ratings, no "hold" ratings, and no "sell" or "strong sell" ratings. Wall Street's median 12-month price target is $59.00, about 32.9% above the August 5 closing price of $44.39.
Cash position strengthened after public offering
The company raised $805 million in a public offering, increasing cash to $1.1 billion at quarter end.
Definium said its current cash and investments are expected to fund operations into 2030.
Q2 loss widens on warrant liability and expense growth
Definium Therapeutics' second-quarter net loss widened, driven by higher warrant liabilities and expenses.
The US biopharma firm said higher research and development expenses were mainly due to increased costs for the DT120 program and expanded personnel. General and administrative expenses rose because of higher stock-based compensation, corporate and government affairs, personnel, and commercial-preparedness costs.
